Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings have been declining at an average annual rate of -9.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 1% per year. Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's return on equity is 4.5%, and it has net margins of 15.2%.
Key information
-9.2%
Earnings growth rate
-11.8%
EPS growth rate
Pharmaceuticals Industry Growth
10.9%
Revenue growth rate
-1.0%
Return on equity
4.5%
Net Margin
15.2%
Last Earnings Update
30 Sep 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
SHSE:688505 Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Sep 24
692
105
257
311
30 Jun 24
736
111
319
280
31 Mar 24
809
102
409
253
31 Dec 23
851
109
450
244
30 Sep 23
1,023
191
539
223
30 Jun 23
1,283
242
694
242
31 Mar 23
1,080
142
630
233
31 Dec 22
1,031
138
597
227
30 Sep 22
1,158
132
739
237
30 Jun 22
1,013
112
650
229
31 Mar 22
1,155
213
675
227
31 Dec 21
1,140
213
666
224
30 Sep 21
1,036
198
579
196
30 Jun 21
997
201
554
183
31 Mar 21
925
188
524
167
31 Dec 20
834
165
482
139
30 Sep 20
901
191
524
135
30 Jun 20
874
165
522
131
31 Mar 20
980
204
622
146
31 Dec 19
1,029
227
588
128
30 Sep 19
848
151
509
130
30 Jun 19
837
151
526
122
31 Mar 19
678
91
397
92
31 Dec 18
742
112
486
114
30 Sep 18
632
95
395
112
30 Jun 18
521
78
305
110
31 Mar 18
510
77
306
110
31 Dec 17
498
75
308
110
30 Sep 17
575
109
355
105
30 Jun 17
652
142
403
99
31 Mar 17
637
141
395
97
31 Dec 16
622
139
386
95
30 Sep 16
615
136
372
104
30 Jun 16
607
134
359
113
31 Mar 16
593
131
348
112
31 Dec 15
579
128
338
110
30 Sep 15
556
125
333
112
30 Jun 15
532
122
327
114
31 Mar 15
501
120
304
109
31 Dec 14
471
118
281
105
30 Sep 14
464
111
269
105
30 Jun 14
412
96
243
79
31 Mar 14
446
98
271
69
31 Dec 13
416
87
253
68
Quality Earnings: 688505 has a large one-off gain of CN¥39.9M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 688505's current net profit margins (15.2%) are lower than last year (18.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688505's earnings have declined by 9.2% per year over the past 5 years.
Accelerating Growth: 688505's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688505 had negative earnings growth (-44.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 688505's Return on Equity (4.5%) is considered low.